NUVB-WT — Nuvation Bio Inc.

Summary of Nuvation Bio Inc. Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $83.2 million for Q1 2026.
• Iptrozy Net U.S. Product Revenue: $18.5 million, an 18% increase from the prior quarter.
• Collaboration and License Revenue: $64.7 million, including a $60 million upfront payment from Eisai.
• Operating Expenses: $73.5 million (R&D: $35 million; SG&A: $38.3 million).
• Cash Position: $533.7 million in cash, cash equivalents, and marketable securities, with an additional $50 million available under a term loan.

2. Strategic Updates and Business Highlights

• Iptrozy Launch: Strong momentum with approximately 200 new patient starts for three consecutive quarters, with over 50% of new patients being TKI-naive.
• Clinical Data: Iptrozy shows a median duration of response of 50 months in TKI-naive patients, reinforcing its efficacy and tolerability.
• NCCN Guidelines: Iptrozy included as a systemic therapy option for ROS1-positive NSCLC patients with brain metastases, enhancing its market positioning.
• Safusitinib Development: Ongoing Phase 3 SIGMA study for IDH1-mutant glioma shows promising efficacy signals, with plans to expand trials into Japan following the acquisition of rights from Daiichi Sankyo.

3. Forward Guidance and Outlook

• Revenue Growth: Anticipated continuation of revenue growth driven by increased first-line patient adoption and improved testing rates.
• Market Potential: The addressable population for ROS1-positive NSCLC could expand with better testing practices, potentially increasing annual diagnoses from 3,000 to 4,000 patients.
• Long-term Strategy: Focus on building a durable patient base and enhancing awareness and testing in community settings to drive future growth.

4. Challenges and Points of Concern

• Patient Discontinuation: Discontinuations primarily driven by disease progression in later-line patients, which could introduce variability in near-term revenue despite steady new patient demand.
• Testing Rates: Lower testing rates in community settings (below 50% in some areas) remain a barrier to patient identification and treatment initiation.
• Competitive Landscape: Emerging competitors with promising data may influence treatment decisions, although Iptrozy's efficacy remains unmatched in the first-line setting.

5. Notable Q&A Insights

• Adoption Dynamics: Both academic and community settings are adopting Iptrozy, but testing rates are higher in academic centers, affecting the diagnosis of new patients.
• Salesforce Expansion: The company is focusing on educational initiatives to improve testing rates in community oncology practices, which is critical for expanding patient access.
• First-Line Patient Dynamics: While new patient starts have plateaued at 200, the increase in first-line patients is expected to stabilize revenue as late-line patients drop off quickly.
• CNS Efficacy: Iptrozy's CNS penetration is highlighted as a significant advantage over competitors, particularly given the prevalence of brain metastases in ROS1-positive NSCLC patients.

Overall, Nuvation Bio Inc. is experiencing solid growth in its Iptrozy launch, supported by strong clinical data and strategic initiatives, but faces challenges related to patient testing and competitive pressures. The company remains optimistic about its future trajectory and the potential for sustained revenue growth.